Sökning: onr:"swepub:oai:DiVA.org:uu-184454" >
Improved Renal Func...
Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus : a Randomized Trial in Kidney Transplantation
-
Mjörnstedt, L. (författare)
-
Sörensen, S. S. (författare)
-
- von zur Mühlen, Bengt (författare)
- Uppsala universitet,Transplantationskirurgi
-
visa fler...
-
Jespersen, B. (författare)
-
Hansen, J. M. (författare)
-
Bistrup, C. (författare)
-
Andersson, H. (författare)
-
Gustafsson, B. (författare)
-
Undset, L. H. (författare)
-
Fagertun, H. (författare)
-
Solbu, D. (författare)
-
Holdaas, H. (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2012
- 2012
- Engelska.
-
Ingår i: American Journal of Transplantation. - : Elsevier BV. - 1600-6135 .- 1600-6143. ; 12:10, s. 2744-2753
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- In an open-label, multicenter trial, de novo kidney transplant recipients at low to medium immunological risk were randomized at week 7 posttransplant to remain on CsA (n = 100, controls) or convert to everolimus (n = 102), both with enteric-coated mycophenolate sodium and corticosteroids. The primary endpoint, change in measured GFR (mGFR) from week 7 to month 12, was significantly greater with everolimus than controls: 4.9 (11.8) mL/min versus 0.0 (12.9) mL/min (p = 0.012; analysis of covariance [ANCOVA]). Per protocol analysis demonstrated a more marked difference: an increase of 8.7 (11.2) mL/min with everolimus versus a decrease of 0.4 (12.0) mL/min in controls (p < 0.001; ANCOVA). There were no differences in graft or patient survival. The 12-month incidence of biopsy-proven acute rejection (BPAR) was 27.5% (n = 28) with everolimus and 11.0% (n = 11) in controls (p = 0.004). All but two episodes of BPAR in each group were mild. Adverse events occurred in 95.1% of everolimus patients and 90.0% controls (p = 0.19), with serious adverse events in 53.9% and 38.0%, respectively (p = 0.025). Discontinuation because of adverse events was more frequent with everolimus (25.5%) than controls (3.0%; p = 0.030). In conclusion, conversion from CsA to everolimus at week 7 after kidney transplantation was associated with a greater improvement in mGFR at month 12 versus CNI-treated controls but discontinuations and BPAR were more frequent.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Nyckelord
- Calcineurin inhibitor
- conversion
- everolimus
- kidney transplantation
- mTOR inhibitor
- switch
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Mjörnstedt, L.
-
Sörensen, S. S.
-
von zur Mühlen, ...
-
Jespersen, B.
-
Hansen, J. M.
-
Bistrup, C.
-
visa fler...
-
Andersson, H.
-
Gustafsson, B.
-
Undset, L. H.
-
Fagertun, H.
-
Solbu, D.
-
Holdaas, H.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kirurgi
- Artiklar i publikationen
-
American Journal ...
- Av lärosätet
-
Uppsala universitet